Trifluridine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Changed protection level for "Trifluridine" ([Edit=Allow only autoconfirmed users] (expires 21:53, 6 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 21:53, 6 January 2014 (UTC))))
No edit summary
Line 1: Line 1:
{{drugbox
__NOTOC__
| IUPAC_name = 1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5- (trifluoromethyl) pyrimidine-2,4-dione
{{Trifluridine}}
| image = Trifluridine.svg
{{CMG}}
| width = 150
| CAS_number = 70-00-8
| ATC_prefix = S01
| ATC_suffix = AD02
| PubChem = 6256
| DrugBank = APRD01275
| C = 10 | H = 11 | F = 3 | N = 2 | O = 5
| molecular_weight = 296.2 g/mol
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life = 12 minutes
| excretion =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- Rx-only -->
| legal_status = Rx-only
| routes_of_administration = Eye drops
}}
'''Trifluridine''' is an anti-[[herpesvirus]] [[antiviral]] drug, used primarily on the [[eye]]. It was sold under the trade name, Viroptic, by Glaxo Wellcome, now merged into [[GlaxoSmithKline]]. The brand is now owned by [[Monarch Pharmaceuticals]], which is wholly owned by [[King Pharmaceuticals]].


It is a [[nucleoside analogue]], a modified form of [[deoxyuridine]], similar enough to be incorporated into viral [[DNA replication]], but the -CF<sub>3</sub> group added to the [[uracil]] component blocks [[base pair]]ing.
==Overview==


==External links==
==Category==
* {{cite journal | author = Costin D, Dogaru M, Popa A, Cijevschi I | title = Trifluridine therapy in herpetic in keratitis | journal = Rev Med Chir Soc Med Nat Iasi | volume = 108 | issue = 2 | pages = 409-12 | year = | id = PMID 15688823}}
Antiviral
* {{cite journal | author = Kuster P, Taravella M, Gelinas M, Stepp P | title = Delivery of trifluridine to human cornea and aqueous using collagen shields. | journal = CLAO J | volume = 24 | issue = 2 | pages = 122-4 | year = 1998 | id = PMID 9571274}}
==US Brand Names==
* {{cite journal | author = O'Brien W, Taylor J | title = Therapeutic response of herpes simplex virus-induced corneal edema to trifluridine in combination with immunosuppressive agents. | journal = Invest Ophthalmol Vis Sci | volume = 32 | issue = 9 | pages = 2455-61 | year = 1991 | id = PMID 1907950}}
VIROPTIC<sup>®</sup>
* {{cite web | url = http://ecatalog.alcon.com/pi/Trifluridine_us_en.pdf | title = Trifluridine Opthalmic Solution, 1% | accessdate = 2007-03-24 | format = PDF}}
==FDA Package Insert==
'''  [[Trifluridine description|Description]]'''
'''| [[Trifluridine clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Trifluridine microbiology|Microbiology]]'''
'''| [[Trifluridine indications and usage|Indications and Usage]]'''
'''| [[Trifluridine contraindications|Contraindications]]'''
'''| [[Trifluridine warnings and precautions|Warnings and Precautions]]'''
'''| [[Trifluridine adverse reactions|Adverse Reactions]]'''
'''| [[Trifluridine overdosage|Overdosage]]'''
'''| [[Trifluridine clinical studies|Clinical Studies]]'''
'''| [[Trifluridine dosage and administration|Dosage and Administration]]'''
'''| [[Trifluridine compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]'''
'''| [[Trifluridine directions for use|Directions For Use]]'''
'''| [[Trifluridine how supplied|How Supplied]]'''
'''| [[Trifluridine labels and packages|Labels and Packages]]'''


{{Antivirals}}
==Mechanism of Action==


{{antimicrobial-stub}}
==References==
[[Category:Antivirals]]
{{Reflist|2}}
 
[[Category:Antibiotics]]
[[Category:Wikinfect]]

Revision as of 04:20, 31 December 2013

Trifluridine
VIROPTIC® FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Category

Antiviral

US Brand Names

VIROPTIC®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages

Mechanism of Action

References

Retrieved from "https://www.wikidoc.org/index.php?title=Trifluridine&oldid=921840"